Top

Published in:

16-08-2023 | Juvenile Dermatomyositis | REVIEW ARTICLE

Biologic drugs in the treatment of juvenile dermatomyositis: a literature review

Authors: Seher Sener, Veysel Cam, Seza Ozen, Ezgi Deniz Batu

Published in: Clinical Rheumatology | Issue 2/2024

Abstract

There is no clear consensus in the literature regarding the choice of biologic therapies and efficacy in juvenile dermatomyositis (JDM). In this review, we aimed to examine previous studies regarding biologic drug use in JDM patients. We screened MEDLINE and Scopus for articles involving JDM patients treated with biologic drugs. We identified 74 articles describing 495 JDM patients treated with biologic drugs (538 biologic treatments) during our literature search. The median (min–max) age of these patients was 9.8 (1–17) years (F/M:1.8). The most frequently used biologic drugs were rituximab (RTX, 50%) and tumor necrosis factor (TNF) inhibitors (34.8%). In a few cases, abatacept (4.3%), anti-interleukin-1 agents (0.9%), tocilizumab (0.9%), bortezomib (0.4%), ustekinumab (0.2%), eculizumab (0.2%), and golimumab (0.2%) were used. RTX was most frequently preferred in patients with severe skin involvement (46.3%). Improvement with RTX was obtained in 60.1% of RTX treatments. Infliximab was most frequently preferred in calcinosis (43.3%), while adalimumab in skin involvement (50%) and etanercept in resistant/recurrent diseases (80%). Improvement was achieved in 44.4% of anti-TNF treatments. Adverse events were observed in 46.8% (58/124) of all treatments. Our results suggest that biologic agents may be a promising alternative for the treatment of particularly resistant JDM cases. Controlled studies are required to provide higher level of evidence for the timing of biologic use in JDM treatment.

Key Points

• There is no consensus on the choice and efficacy of biologic therapies in JDM.

• RTX and TNF inhibitors are the most commonly used biologic drugs.

• Biologics were especially preferred in severe skin involvement, calcinosis, and resistant diseases.

Available only for authorised users

Orandi AB, Dharnidharka VR, Al-Hammadi N, Baszis KW, Abramson L, Anderson E et al (2018) Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis. Pediatr Rheumatol Online J 16(1):84. https://doi.org/10.1186/s12969-018-0299-9CrossRefPubMedPubMedCentral

Spencer CH, Rouster-Stevens K, Gewanter H, Syverson G, Modica R, Schmidt K et al (2017) Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the childhood arthritis and rheumatology research alliance in north america. Pediatr Rheumatol Online J 15(1):50CrossRefPubMedPubMedCentral

Rider LG (2007) The heterogeneity of juvenile myositis. Autoimmun Rev 6(4):241–247. https://doi.org/10.1016/j.autrev.2006.08.009CrossRefPubMed

Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C et al (2010) Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken) 62(1):63–72CrossRefPubMed

Ramanan AV, Feldman BM (2002) Clinical outcomes in juvenile dermatomyositis. Curr Opin Rheumatol 14(6):658–662. https://doi.org/10.1097/00002281-200211000-00005CrossRefPubMed

Orandi A, Baszis K, Dharnidharka V, Huber A, Hoeltzel M (2017) Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA). Pediatr Rheumatol Online J 15(1):71. https://doi.org/10.1186/s12969-017-0199-4CrossRefPubMedPubMedCentral

De Paepe B, Zschüntzsch J (2015) Scanning for therapeutic targets within the cytokine network of idiopathic inflammatory myopathies. Int J Mol Sci 16(8):18683–18713CrossRefPubMedPubMedCentral

Boulter EL, Beard L, Ryder C, Pilkington CA (2011) Effectiveness of anti-TNF-α agents in the treatment of refractory juvenile dermatomyositis. Pediatr Rheumatol Online J 9(Suppl 1):O29. https://doi.org/10.1186/1546-0096-9-S1-O29CrossRefPubMedCentral

Prasad S, Misra R, Agarwal V, Lawrence A, Aggarwal A (2013) Juvenile dermatomyositis at a tertiary care hospital: is there any change in the last decade? Int J Rheum Dis 16(5):556–560. https://doi.org/10.1111/1756-185X.12053CrossRefPubMed

10.

Perna DL, Callen JP, Schadt CR (2022) Association of treatment with secukinumab with exacerbation of dermatomyositis in a patient with psoriasis. JAMA Dermatol 158(4):454–456. https://doi.org/10.1001/jamadermatol.2021.6011CrossRefPubMed

11.

Curiel RV, Nguyen W, Mamyrova G, Jones D, Ehrlich A, Brindle KA et al (2023) Improvement in disease activity in refractory juvenile dermatomyositis following abatacept therapy. Arthritis Rheumatol. https://doi.org/10.1002/art.42450CrossRefPubMed

12.

Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC et al (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65(2):314–324CrossRefPubMedPubMedCentral

13.

Montoya C, Gonzalez M, Ospina F, Tobón G (2017) A rare case of amyopathic juvenile dermatomyositis associated with psoriasis successfully treated with ustekinumab. J Clin Rheumatol 23(2):129–130. https://doi.org/10.1097/RHU.0000000000000430CrossRefPubMed

14.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https://doi.org/10.1136/bmj.n71CrossRefPubMedPubMedCentral

15.

Le Voyer T, Gitiaux C, Authier F-J, Bodemer C, Melki I, Quartier P et al (2021) JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study. Rheumatology (Oxford) 60(12):5801–5808. https://doi.org/10.1093/rheumatology/keab116CrossRefPubMed

16.

Aeschlimann FA, Frémond M-L, Duffy D, Rice GI, Charuel J-L, Bondet V et al (2018) A child with severe juvenile dermatomyositis treated with ruxolitinib. Brain 141(11):e80CrossRefPubMed

17.

Aggarwal R, Loganathan P, Koontz D, Qi Z, Reed AM, Oddis CV (2017) Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. Rheumatology (Oxford) 56(2):247–254CrossRefPubMed

18.

Al-Mayouf SM, AlMutiari N, Muzaffer M, Shehata R, Al-Wahadneh A, Abdwani R et al (2017) Phenotypic characteristics and outcome of juvenile dermatomyositis in Arab children. Rheumatol Int 37(9):1513–1517CrossRefPubMed

19.

Althagafi HO, Morishita K, Petty RE (2013) Severe vocal cord dysfunction: an unusual complication of juvenile dermatomyositis. J Rheumatol 40(5):744–745CrossRefPubMed

20.

Arabshahi B, Silverman RA, Jones OY, Rider LG (2012) Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. J Pediatr 160(3):520–522. https://doi.org/10.1016/j.jpeds.2011.11.057CrossRefPubMedPubMedCentral

21.

Barut K, Aydin POA, Adrovic A, Sahin S, Kasapcopur O (2017) Juvenile dermatomyositis: a tertiary center experience. Clin Rheumatol 36(2):361–366. https://doi.org/10.1007/s10067-016-3530-4CrossRefPubMed

22.

Besançon A, Brochard K, Dupic L, Gitiaux C, Delville M, Krid S et al (2017) Presentations and outcomes of juvenile dermatomyositis patients admitted to intensive care units. Rheumatology (Oxford) 56(10):1814–1816. https://doi.org/10.1093/rheumatology/kex267CrossRefPubMed

23.

Besnard C, Gitiaux C, Girard M, Galmiche-Rolland L, Talbotec C, Quartier P et al (2020) Severe abdominal manifestations in juvenile dermatomyositis. J Pediatr Gastroenterol Nutr 70(2):247–251. https://doi.org/10.1097/MPG.0000000000002575CrossRefPubMed

24.

Cannon L, Dvergsten J, Stingl C (2020) Juvenile dermatomyositis and development of malignancy: 2 case reports and a literature review. J Rheumatol 47(3):479CrossRefPubMed

25.

Chan Ng PLP, Mopur A, Goh DYT, Ramamurthy MB, Lim MTC, Lim LK et al (2022) Janus kinase inhibition in induction treatment of anti-MDA5 juvenile dermatomyositis-associated rapidly progressive interstitial lung disease. Int J Rheum Dis 25(2):228–231. https://doi.org/10.1111/1756-185X.14258CrossRefPubMed

26.

Choi RY, Swan RJ, Hersh A, Vitale AT (2018) Retinal manifestations of juvenile dermatomyositis: case report of bilateral diffuse chorioretinopathy with paracentral acute middle maculopathy and review of the literature. Ocul Immunol Inflamm 26(6):929–933. https://doi.org/10.1080/09273948.2017.1305421CrossRefPubMed

27.

Cooper MA, Willingham DL, Brown DE, French AR, Shih FF, White AJ (2007) Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum 56(9):3107–3111. https://doi.org/10.1002/art.22856CrossRefPubMed

28.

Ding Y, Huang B, Wang Y, Hou J, Chi Y, Zhou Z et al (2021) Janus kinase inhibitor significantly improved rash and muscle strength in juvenile dermatomyositis. Ann Rheum Dis 80(4):543–545. https://doi.org/10.1136/annrheumdis-2020-218582CrossRefPubMed

29.

Faller G, Mistry BJ, Tikly M (2014) Juvenile dermatomyositis in South African children is characterised by frequent dystropic calcification: a cross sectional study. Pediatr Rheumatol Online J 12:2. https://doi.org/10.1186/1546-0096-12-2CrossRefPubMedPubMedCentral

30.

Fotis L, Baszis KW, White AJ, French AR (2016) Four cases of anti-PM/Scl antibody-positive juvenile overlap syndrome with features of myositis and systemic sclerosis. J Rheumatol 43(9):1768–1769. https://doi.org/10.3899/jrheum.151445CrossRefPubMed

31.

Hassas Yeganeh M, Ahmadi P, Nilipour Y, Mousavi Khorshidi MS, Sinaei R, Fathi MR et al (2020) A dermatopathic juvenile dermatomyositis; an unexpected case in childhood. Iran J Child Neurol 14(3):89–92PubMedPubMedCentral

32.

Heinen A, Schnabel A, Brück N, Smitka M, Wolf C, Lucas N et al (2021) Interferon signature guiding therapeutic decision making: ruxolitinib as first-line therapy for severe juvenile dermatomyositis? Rheumatology (Oxford) 60(4):e136–e138CrossRefPubMed

33.

Holzer U, van Royen-Kerkhof A, Van Der Torre P, Kuemmerle-Deschner J, Well C, Handgretinger R et al (2010) Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis. Scand J Rheumatol 39(1):88–92. https://doi.org/10.3109/03009740903096622CrossRefPubMed

34.

Jansson AF, Sengler C, Kuemmerle-Deschner J, Gruhn B, Kranz AB, Lehmann H et al (2011) B cell depletion for autoimmune diseases in paediatric patients. Clin Rheumatol 30(1):87–97. https://doi.org/10.1007/s10067-010-1630-0CrossRefPubMed

35.

Khan H, Mehta P, Gupta L (2021) Juvenile dermatomyositis with gingival vasculopathy. Clin Rheumatol 40(8):3369–3370CrossRefPubMed

36.

Kim LH, Duncan J, Yang CL (2021) Juvenile dermatomyositis and acute respiratory failure in a teen. Chest 160(6):e619–e622CrossRefPubMed

37.

Kim NN, Lio PA, Morgan GA, Jarvis JN, Pachman LM (2011) Double trouble: therapeutic challenges in patients with both juvenile dermatomyositis and psoriasis. Arch Dermatol 147(7):831–835CrossRefPubMed

38.

Lanis A, Volochayev R, Kleiner DE, Vittal A, Heller T, Rider LG et al (2022) Nodular regenerative hyperplasia of the liver in juvenile dermatomyositis. Pediatr Rheumatol Online J 20(1):30. https://doi.org/10.1186/s12969-022-00690-xCrossRefPubMedPubMedCentral

39.

Lieberman SM, Sherry DD (2009) Development of classic dermatomyositis rash years after diagnosis of juvenile polymyositis. J Clin Rheumatol 15(6):316–318. https://doi.org/10.1097/RHU.0b013e3181b18cddCrossRefPubMed

40.

Luca NJ, Atkinson A, Hawkins C, Feldman BM (2012) Anti-signal recognition particle-positive juvenile polymyositis successfully treated with rituximab. J Rheumatol 39(7):1483–1485. https://doi.org/10.3899/jrheum.111592CrossRefPubMed

41.

Melki I, Devilliers H, Gitiaux C, Bondet V, Duffy D, Charuel J-L et al (2020) Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-α signalling. Rheumatology (Oxford) 59(8):1927–1937CrossRefPubMed

42.

Mrosak J, Banasiak K, Edelheit B, Lapin C, Tory H, Collins MS (2021) Polymyxin-B hemoperfusion as a novel treatment for rapidly progressive interstitial lung disease in a pediatric patient diagnosed with anti-MDA5 juvenile dermatomyositis. J Clin Rheumatol 27(8S):S480–S484. https://doi.org/10.1097/RHU.0000000000001191CrossRefPubMed

43.

Ochfeld E, Hans V, Marin W, Ahsan N, Morgan G, Pachman LM et al (2022) Coding joint: kappa-deleting recombination excision circle ratio and B cell activating factor level: predicting juvenile dermatomyositis rituximab response, a proof-of-concept study. BMC Rheumatol 6(1):36. https://doi.org/10.1186/s41927-022-00265-zCrossRefPubMedPubMedCentral

44.

Okong’o LO, Esser M, Wilmshurst J, Scott C (2016) Characteristics and outcome of children with juvenile dermatomyositis in Cape Town: a cross-sectional study. Pediatr Rheumatol Online J 14(1):60. https://doi.org/10.1186/s12969-016-0118-0CrossRefPubMedPubMedCentral

45.

Orandi AB, Dharnidharka VR, Al-Hammadi N, Baszis KW (2018) Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis. Pediatr Rheumatol Online J 16(1):84. https://doi.org/10.1186/s12969-018-0299-9CrossRefPubMedPubMedCentral

46.

Papadopoulou C, Hong Y, Omoyinmi E, Brogan PA, Eleftheriou D (2019) Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis. Brain 142(3):e8CrossRefPubMedPubMedCentral

47.

Quintana-Ortega C, Remesal A, Ruiz de Valbuena M, de la Serna O, Laplaza-González M, Álvarez-Rojas E et al (2021) Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report. Mod Rheumatol Case Rep 5(1):101–107. https://doi.org/10.1080/24725625.2020.1832755CrossRefPubMedPubMedCentral

48.

Rider LG, Yip AL, Horkayne-Szakaly I, Volochayev R, Shrader JA, Turner ML et al (2014) Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial. Clin Exp Rheumatol 32(5):689–696PubMedPubMedCentral

49.

Riley P, McCann L, Maillard S, Woo P, Murray K, Pilkington C (2008) Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 47(6):877–880CrossRefPubMed

50.

Rouster-Stevens KA, Ferguson L, Morgan G, Huang CC, Pachman LM (2014) Pilot study of etanercept in patients with refractory juvenile dermatomyositis. Arthritis Care Res (Hoboken) 66(5):783–787. https://doi.org/10.1002/acr.22198CrossRefPubMed

51.

Sabbagh S, Almeida de Jesus A, Hwang S, Kuehn HS, Kim H, Jung L et al (2019) Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. Brain 142(11):e59CrossRefPubMedPubMedCentral

52.

Sabbagh SE, Neely J, Chow A, DeGuzman M, Lai J, Lvovich S et al (2021) Risk factors associated with pneumocystis jirovecii pneumonia in juvenile myositis in North America. Rheumatology (Oxford) 60(2):829–836CrossRefPubMed

53.

Sallum AME, Silva MFC, Michelin CM, Duarte RJ, Baroni RH, Aikawa NE et al (2011) Penile and scrotum swelling in juvenile dermatomyositis. Acta Reumatol Port 36(2):176–179PubMed

54.

Sanner H, Sjaastad I, Flatø B (2014) Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool. Rheumatology (Oxford) 53(9):1578–1585CrossRefPubMed

55.

Schildt EE, De Ranieri D (2021) Anasarca as the presenting symptom of juvenile dermatomyositis: a case series. Pediatr Rheumatol Online J 19(1):120. https://doi.org/10.1186/s12969-021-00604-3CrossRefPubMedPubMedCentral

56.

Shimizu M, Inoue N, Takeda Y, Kidouchi K, Fujita N, Fujiki T et al (2021) Concurrent treatment with rituximab and plasma exchange for rapidly progressive interstitial lung disease complicating anti-mda5 antibody-positive juvenile dermatomyositis. J Clin Rheumatol 27(8S):S798–S799. https://doi.org/10.1097/RHU.0000000000001460CrossRefPubMed

57.

Sözeri B, Demir F (2020) A striking treatment option for recalcitrant calcinosis in juvenile dermatomyositis: tofacitinib citrate. Rheumatology (Oxford) 59(12):e140–e141CrossRefPubMed

58.

Tansley SL, Betteridge ZE, Simou S, Jacques TS, Pilkington C, Wood M et al (2017) Anti-HMGCR autoantibodies in juvenile idiopathic inflammatory myopathies identify a rare but clinically important subset of patients. J Rheumatol 44(4):488–492. https://doi.org/10.3899/jrheumCrossRefPubMed

59.

Toplak N, Chavan PP, Rosina S, Dallos T, Semo OR, Aguiar CL et al (2021) Is Anti-NXP2 autoantibody a risk factor for calcinosis and poor outcome in juvenile dermatomyositis patients? Case Series. Front Pediatr 9:810785. https://doi.org/10.3389/fped.2021.810785CrossRefPubMed

60.

Tzaribachev N, Koetter I, Kuemmerle-Deschner JB, Schedel J (2009) Rituximab for the treatment of refractory pediatric autoimmune diseases: a case series. Cases J 2:6609. https://doi.org/10.1186/1757-1626-0002-0000006609CrossRefPubMedPubMedCentral

61.

Uejima Y, Suganuma E, Kawano Y, Sato S (2020) Anti-MDA5 antibody-positive juvenile dermatomyositis overlap with neuropsychiatric systemic lupus erythematosus: a case report. Clin Exp Rheumatol 39(1):27–28PubMed

62.

Vaiyani D, Edelson JB, Gmuca S, O’Connor MJ, Mille FK (2021) Juvenile dermatomyositis: a rare but treatable cause of acute myocardial dysfunction. J Clin Rheumatol 27(8S):S777–S778. https://doi.org/10.1097/RHU.0000000000001489CrossRefPubMed

63.

Vargas Lebrón C, Ruiz Montesino MD, Moreira Navarrete V, Toyos Sainz de Miera FJ (2020) Treatment with rituximab in juvenile dermatomyositis: effect on calcinosis. Reumatol Clin (Engl Ed) 16(5 Pt 1):368–370. English, Spanish. https://doi.org/10.1016/j.reuma.2018.06.010

64.

Varnier GC, Consolaro A, Maillard S, Pilkington C, Ravelli A (2021) Comparison of treatments and outcomes of children with juvenile dermatomyositis followed at two European tertiary care referral centers. Rheumatology (Oxford) 60(11):5419–5423CrossRefPubMed

65.

Wang C-R (2017) Successful treatment of refractory juvenile dermatomyositis with adalimumab. J Clin Rheumatol 23(3):174–175. https://doi.org/10.1097/RHU.0000000000000514CrossRefPubMed

66.

Wang X, Ding Y, Zhou Z, Hou J, Xu Y, Li J (2021) Clinical characteristics and poor predictors of anti-NXP2 antibody-associated Chinese JDM children. Pediatr Rheumatol Online J 19(1):6CrossRefPubMedPubMedCentral

67.

Yeşilbaş O, Yildiz M, Yozgat CY, Tahaoglu I, Yazan H, Cakir E et al (2021) A fatal interstitial lung disease in an anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody negative patient with juvenile dermatomyositis. Turk J Pediatr 63(5):903–908. https://doi.org/10.24953/turkjped.2021.05.018CrossRefPubMed

68.

Nishi K, Ogura M, Tamai N, Gima M, Ide K, Koinuma G et al (2022) Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review. Pediatr Rheumatol Online J 20(1):60CrossRefPubMedPubMedCentral

69.

Horn S, Minden K, Speth F, Schwarz T, Dressler F, Grösch N et al (2022) Myositis-specific autoantibodies and their associated phenotypes in juvenile dermatomyositis: data from a German cohort. Clin Exp Rheumatol 40(2):433–442CrossRefPubMed

70.

Papadopoulou C, Hong Y, Krol P, Al Obaidi M, Pilkington C, Wedderburn Lucy R et al (2021) The vasculopathy of juvenile dermatomyositis: endothelial injury, hypercoagulability, and increased arterial stiffness. Arthritis Rheumatol 73(7):1253–1266. https://doi.org/10.1002/art.41639CrossRefPubMed

71.

Perron MM, Vasquez-Canizares N, Tarshish G, Wahezi DM (2021) Myositis autoantibodies in a racially diverse population of children with idiopathic inflammatory myopathies. Pediatr Rheumatol Online J 19(1):92. https://doi.org/10.1186/s12969-021-00574-6CrossRefPubMedPubMedCentral

72.

Lerkvaleekul B, Veldkamp SR, van der Wal MM, Schatorjé EJH, Kamphuis SSM, van den Berg JM et al (2022) Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response. Rheumatology (Oxford) 61(5):2144–2155CrossRefPubMed

73.

Stewart JA, Price T, Moser S, Mullikin D, Bryan A (2022) Progressive, refractory macrophage activation syndrome as the initial presentation of anti-MDA5 antibody positive juvenile dermatomyositis: a case report and literature review. Pediatr Rheumatol Online J 20(1):16CrossRefPubMedPubMedCentral

74.

Yeung TW, Cheong KN, Lau YL, Tse KN (2021) Adolescent-onset anti-MDA5 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and spontaneous pneumomediastinum: a case report and literature review. Pediatr Rheumatol Online J 19(1):103CrossRefPubMedPubMedCentral

75.

Hussain A, Rawat A, Jindal AK, Gupta A, Singh S (2017) Autoantibodies in children with juvenile dermatomyositis: A single centre experience from North-West India. Rheumatol Int 37(5):807–812. https://doi.org/10.1007/s00296-017-3707-4CrossRefPubMed

76.

Campanilho-Marques R, Deakin CT, Simou S, Papadopoulou C, Wedderburn LR, Pilkington CA (2020) Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients. Arthritis Res Ther 22(1):79CrossRefPubMedPubMedCentral

77.

Wang Z, Zheng Q, Xuan W, Xu X, Lu M, Wu J et al (2022) Short-term effectiveness of baricitinib in children with refractory and/or severe juvenile dermatomyositis. Front Pediatr 10:962585CrossRefPubMedPubMedCentral

78.

Jin J, Yu H (2022) Use of adalimumab in a child with juvenile dermatomyositis and calcinosis. Indian J Pediatr 89(12):1270. https://doi.org/10.1007/s12098-022-04332-8CrossRefPubMed

79.

Gofshteyn J, Mansfield L, Spitznagle J, Balasubramanian P, Cardenas J, Miller T et al (2023) Juvenile dermatomyositis disease activity is associated with the expansion of blood B and T-cell memory subsets lacking follicular markers. Arthritis Rheumatol. https://doi.org/10.1002/art.42446CrossRefPubMed

80.

Cancarini P, Nozawa T, Whitney K, Bell-Peter A, Marcuz J-A, Taddio A et al (2022) The clinical features of juvenile dermatomyositis: A single-centre inception cohort. Semin Arthritis Rheum 57:152104. https://doi.org/10.1016/j.semarthrit.2022.152104CrossRefPubMed

81.

Bader-Meunier B, Decaluwe H, Barnerias C, Gherardi R, Quartier P, Faye A et al (2011) Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the french autoimmunity and rituximab registry. J Rheumatol 38(7):1436–1440. https://doi.org/10.3899/jrheum.101321CrossRefPubMed

82.

Dinh HV, McCormack C, Hall S, Prince HM (2007) Rituximab for the treatment of the skin manifestations of dermatomyositis: A report of 3 cases. J Am Acad Dermatol 56(1):148–153. https://doi.org/10.1016/j.jaad.2006.05.068CrossRefPubMed

83.

Sukumaran S, Vijayan V (2020) Abatacept in the treatment of juvenile dermatomyositis-associated calcifications in a 16-year-old girl. Case Rep Rheumatol 2020:4073879. https://doi.org/10.1155/2020/4073879CrossRefPubMedPubMedCentral

84.

Lilleby V, Haydon J, Sanner H, Krossness BK, Ringstad G, Flatø B (2014) Severe macrophage activation syndrome and central nervous system involvement in juvenile dermatomyositis. Scand J Rheumatol 43(2):171–173. https://doi.org/10.3109/03009742.2013.863968CrossRefPubMed

85.

Sun C, Lee JH, Yang YH, Yu HH, Wang LC, Lin YT et al (2015) Juvenile dermatomyositis: a 20-year retrospective analysis of treatment and clinical outcomes. Pediatr Neonatol 56(1):31–39CrossRefPubMed

86.

Wu Q, Wedderburn LR, McCann LJ (2017) Juvenile dermatomyositis: latest advances. Best Pract Res Clin Rheumatol 31(4):535–557. https://doi.org/10.1016/j.berh.2017.12.003CrossRefPubMed

87.

Kuye IO, Smith GP (2017) The use of rituximab in the management of refractory dermatomyositis. J Drugs Dermatol 16(2):162–166PubMed

88.

Marie I, Mouthon L (2011) Therapy of polymyositis and dermatomyositis. Autoimmun Rev 11(1):6–13. https://doi.org/10.1016/j.autrev.2011.06.007CrossRefPubMed

89.

Klein R, Rosenbach M, Kim EJ, Kim B, Werth VP, Dunham J (2010) Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol 146(7):780–784CrossRefPubMedPubMedCentral

90.

Brunasso AM, Aberer W, Massone C (2014) New onset of dermatomyositis/polymyositis during anti-TNF-α therapies: a systematic literature review. ScientificWorldJournal 2014:179180. https://doi.org/10.1155/2014/179180CrossRefPubMedPubMedCentral

91.

Oddis CV, Rockette HE, Zhu L, Koontz DC, Lacomis D, Venturupalli S, et al (2022) Randomized trial of tocilizumab in the treatment of refractory adult polymyositis and dermatomyositis. ACR Open Rheumatol 4(11):983–990

92.

Patil A, Lu J, Kassir M, Babaei M, Goldust M (2023) Adult and juvenile dermatomyositis treatment. J Cosmet Dermatol 22(2):395–401. https://doi.org/10.1111/jocd.15363CrossRefPubMed

93.

Kul Cinar O, Papadopoulou C, Pilkington CA (2021) Treatment of calcinosis in juvenile dermatomyositis. Curr Rheumatol Rep 23(2):1–15. https://doi.org/10.1007/s11926-020-00974-9CrossRef

94.

Bellutti Enders F, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman B et al (2017) Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis 76:329–340. https://doi.org/10.1136/annrheumdis-2016-209247CrossRefPubMed

95.

Orandi AB, Baszis KW, Dharnidharka VR, Huber AM, Hoeltzel MF, CARRA Juvenile Myositis subgroup (2017) Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA). Pediatr Rheumatol Online J 15(1):1–10. https://doi.org/10.1186/s12969-017-0199-4CrossRef

96.

Lichtenstein L, Ron Y, Kivity S, Ben-Horin S, Israeli E, Fraser GM et al (2015) Infliximab-Related Infusion Reactions: Systematic Review. J Crohns Colitis 9(9):806–815CrossRefPubMedPubMedCentral

Title: Biologic drugs in the treatment of juvenile dermatomyositis: a literature review
Authors: Seher Sener
Veysel Cam
Seza Ozen
Ezgi Deniz Batu
Publication date: 16-08-2023
Publisher: Springer International Publishing
Keywords: Juvenile Dermatomyositis
Rituximab
Rituximab
Abatacept
Infliximab
Etanercept
Adalimumab
Tocilizumab
Ustekinumab
Golimumab
Published in: Clinical Rheumatology / Issue 2/2024
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-023-06740-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2024

Examining the link between TNF inhibition and alopecia areata using Mendelian randomization

Sema4D as a biomarker for Predicting rheumatoid arthritis disease activity

Does baricitinib reduce disease activity in patients with systemic lupus erythematosus? A systematic review and meta-analysis of randomized controlled trials

Unusual pleural effusion in a patient with rheumatoid arthritis: chylothorax

ToRaRI (Tofacitinib in Rheumatoid Arthritis a Real-Life experience in Italy): Effectiveness, safety profile of tofacitinib and concordance between patient-reported outcomes and physician's global assessment of disease activity in a retrospective study in Central-Italy

Response to: comment on “validation and predictive capacity of a dutch version of the FLARE‐RA questionnaire within the context of a TNFi‐tapering trial”

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials